# Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

> **NCT03802630** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 450 (actual)

## Conditions studied

- Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Brolucizumab 6 mg
- **DRUG:** Aflibercept 2 mg
- **OTHER:** Sham injection

## Key facts

- **NCT ID:** NCT03802630
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-02
- **Primary completion:** 2021-07-26
- **Final completion:** 2021-07-26
- **Target enrollment:** 450 (ACTUAL)
- **Why stopped:** Study was terminated by sponsor due to increased incidences of AEs of special interest (intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03802630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03802630, "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03802630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*